论文部分内容阅读
通过对保尔佳配合放、化疗治疗中、晚期恶性肿瘤的临床研究。结果表明：治疗组生活质量改善明显优于对照组（P＜0．01）；治疗组与对照组抗肿瘤疗效分别为73．3％和62．7％，两者无显著差异（P＞0．05）；白细胞计数在治疗组治疗后与治疗前相比无明显下降（P＞0．05），而对照组则有不同程度下降（P＜0．01）；两组相比有极显著差异（P＜0．01）；治疗组与对照组相比，CD3＋、CD4+、CD8+在治疗前无显著性差异（P＞0．05），治疗后1～3个月有极显著性差异（P＜0．01）。作者认为保尔佳确有显著抑制肿瘤生长，稳定病情，增强机体免疫功能，改善生活质量，减轻放、化疗毒性，提高患者对放、化疗的耐受性的作用。
Through the clinical research on the treatment of malignant tumors in the middle and late stages of the treatment of Polgi with radiotherapy and chemotherapy. The results showed that the quality of life of the treatment group was significantly better than that of the control group (P<0.01). The anti-tumor efficacy of the treatment group and the control group was 73.3% and 62.7%, respectively. There was no significant difference between the two groups (P>0). .05); WBC count did not decrease significantly after treatment in the treatment group compared with before treatment (P>0.05), but decreased in the control group to varying degrees (P<0.01); there was significant difference between the two groups. Differences (P<0.01); There was no significant difference in CD3+, CD4+, and CD8+ between the treatment group and the control group before treatment (P>0.05), and there was a significant difference between the treatment and the treatment group (1-3 months). P<0.01). The author believes that Paul has a significant inhibition of tumor growth, to stabilize the condition, enhance immune function, improve quality of life, reduce toxicity of radiotherapy and chemotherapy, improve patient tolerance to radiotherapy and chemotherapy.